

Supplemental Figure 1 Design of phase IB combination study of toripalimab plus axitinib in treating patients with mucosal melanoma and clinical efficacy summary. DLT, dose-limiting toxicity; IV, intravenous; PD, progressive disease; PR, partial response; SD, stable disease.

Supplemental Figure 2 CONSORT diagram for phase IB combination study of toripalimab with axitinib in treating patients with mucosal melanoma.

Supplemental Figure 3 The correlation of clinical response with inflammation or angiogenesis signature panel scores. McDermott et al.²² inflammation panel: IL-6, CXCL1, CXCL2, CXCL3, CXCL8, and PTGS2; McDermott et al.²² angiogenesis panel: VEGFA, KDR, ESM1, PECAM1, ANGPTL4, and CD34; Ayers et al.²³ inflammation panel: IDO1, CXCL10, CXCL9, HLADRA, STAT1, and IFN- γ . Responders are those with complete or partial response; non-responders are those with stable or progressive disease.